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Abstract 
Mesenchymal stromal cells (MSC) can be isolated from several regions of human umbilical 
cords, including Wharton’s jelly (WJ), artery, vein or cord lining. These MSC appear to be 
immune privileged and are promising candidates for cell therapy.  However, isolating MSC 
from WJ, artery, vein or cord lining requires time-consuming tissue dissection.  MSC can be 
obtained easily via briefly digesting complete segments of the umbilical cord, likely 
containing heterogenous or mixed populations of MSC (MC-MSC).   MC-MSC are generally 
less well characterised than WJ-MSC, but nevertheless represent a potentially valuable 
population of MSC.  This study aimed to further characterise MC-MSC in comparison to WJ-
MSC and also the better-characterised bone marrow-derived MSC (BM-MSC).  MC-MSC 
proliferated faster; with significantly faster doubling times reaching passage one 8.8 days 
sooner and surviving longer in culture than WJ-MSC.  All MSC retained the safety aspect of 
reducing telomere length with increasing passage number.  MSC were also assessed for their 
ability to suppress T cell proliferation and for the production of key markers of pluripotency, 
embryonic stem cells, tolerogenicity (CD40, CD80, CD86 and HLA-DR) and 
immunomodulation (indoleamine 2,3-dioxygenase [IDO] and HLA-G).   The MC-MSC 
population displayed all of the positive attributes of WJ-MSC and BM-MSC, but they were 
more efficient to obtain and underwent more population doublings than from WJ, suggesting 
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that MC-MSC are promising candidates for allogeneic cell therapy in regenerative 
medicine.   
 
Keywords 
Bone-marrow-derived mesenchymal stromal cells; umbilical-cord-derived mesenchymal 
stromal cells; immunomodulation; allogeneic cell therapy. 
 
Introduction 
Mesenchymal stromal cells (MSC) from umbilical cords are of increasing interest for cell 
therapy for many areas of regenerative medicine, including the treatment of degenerative 
musculoskeletal disorders, as they are well-supported by medical ethics and are reported to 
contain immune privileged cells, rendering them potentially suitable for allogeneic therapies 
[1].  The use of autologous cells for cell therapies has perceived advantages related to low 
risk of immune rejection. Nevertheless, cells taken from older patients, to treat age-related 
musculoskeletal disorders such as arthritis may not grow well in culture [2] and patients often 
have to undergo two operations, the first to obtain the cells and the second to implant them. 
Allogeneic cell banks, providing an ‘off the shelf’ cell product, would alleviate the need for 
two surgical procedures. Furthermore, patients with a degenerate condition may have 
inherited defective genes in a particular cell type. Thus a characterised allogeneic cell may 
have the potential of providing an improved genotype and so a better quality tissue than a 
defective autologous cell.    The use of MSC as an allogeneic treatment in the clinic may only 
be possible if they proliferate well enough in culture at a low passage number to create cell 
banks. The proliferative capacity of MSC at low passage may be critical to forming useful 
cell banks since there are recent reports that BM-MSC at high passage number (passage 5 to 
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10) may have diminished efficiency and reduced therapeutic effect in vivo [3]. The mode of 
action of MSC remains to be confirmed, but rather than them differentiating in vivo into 
repair tissues, there is an increasing body of evidence from in vitro and in vivo studies 
suggesting that MSC function through trophic effects on endogenous cells as well as by 
secretion of immunomodulatory molecules [4–6]. Indeed, Velthoven et al [7] have shown 
that they may not survive long enough to differentiate at all. 
It is also well known that the ability of MSC to modulate inflammatory processes or become 
‘immunomodulating’ cells is enhanced by stimulation with pro-inflammatory cytokines, 
TNF-α, IL-1β and interferon-γ (IFN-γ) [8, 9]. Indeed, the International Society for Cell 
Therapy (ISCT) working proposal advises that characterisation of stem cells for therapy 
should include activation or ‘licensing’, which involves stimulation with IFN-γ, either alone 
or with the addition of TNF-α [8]. The production of potent immunomodulating molecules, 
such as indoleamine 2,3-dioxygenase (IDO), only occurs following cell activation with one 
or more of these inflammatory cytokines. 
Due to their derivation from postembryonic tissue, MSC derived from umbilical cord exhibit 
some of the properties of embryonic stromal cells (ESC), but they also share characteristics 
with BM-MSC derived from adult tissue. Unlike BM-MSC, ESC do not up-regulate MHC 
II/HLA-DR molecules after stimulation with IFN-γ [10]. ESC are also well characterised as 
being pluripotent cells, that lack stage specific embryonic antigen (SSEA)-1, and produce 
SSEA-4, alkaline phosphatase, tumour repressor antigen (TRA)-1-60, TRA-1-81, OCT3/4, 
nanog, and REX-1.  Reports of pluripotency and immunomodulatory capacity of UC-MSC 
and BM-MSC are more variable, possibly due to different culture conditions. In previous 
work our group isolated and characterised MSC from four distinct anatomical regions of the 
human UC: the umbilical vein, arteries, cord lining and WJ, and from a population isolated 
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from the whole cord/mixed cord after enzyme treatment [11]. All populations of cells were 
found to fit the MSC profile, according to the ISCT criteria. We did not identify any distinct 
differences between them except that cells isolated from MC and WJ showed slightly better 
differentiation potential than cells isolated from other cord regions, indicating MC-MSC and 
WJ-MSC to be the most promising candidates for regenerative cell therapies. In the light of 
new research showing that the mechanism of action may not be primarily through 
differentiation the focus of this study was to further characterise and examine potential 
immunomodulatory properties of MSC from WJ or whole human umbilical cord 
preparations, for a direct comparison of which cell type may be more suitable for 
regenerative cell therapies.   
In addition to assessing telomere length and the presence of embryonic and pluripotent 
markers, we also analysed the immune properties of these cells before and after stimulation 
with the pro-inflammatory cytokine IFN- and compared their responses to those of the well-
characterised BM-MSC.     
 
Materials & Methods 
Isolation and culture of cells from human umbilical cords and bone marrow 
All samples were obtained after patients had provided informed consent; favourable ethical 
approval was given by the National Research Ethics Service (10/H10130/62). UCs were 
collected and processed within 24 h of natural delivery, as previously described [11]. All 
cells were grown in ‘complete’ media containing Dulbecco’s Modified Eagle’s Medium 
(DMEM F12), 10% foetal calf serum (FCS; Life Technologies, Paisley, UK) and 1% 
penicillin/streptomycin (P/S; Life Technologies, UK).  MC-MSC were obtained by 
processing 2-3 cm of whole UC, which were weighed and minced into small pieces (~2 mm3) 
before digesting with 1mg/ml collagenase I        (> 125 digesting units/mg; Sigma-Aldrich, 
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Dorset, UK) for 1 h at 37°C. Tissue was removed from the digest and the supernatant was 
centrifuged at 80 g for 10 min; the pellet was re-suspended in 5 ml of medium and plated into 
a 25 cm2 tissue culture flask (Sarstedt, Leicester, UK).  WJ was dissected from approximately 
6 cm of whole cord, weighed, minced and placed into a 25 cm2 tissue culture flask for explant 
culture. Tissue was removed after 21 days of culture.  
In addition, human BM-MSC were obtained for comparison, from bone chips, harvested from 
the iliac crest of patients undergoing spinal fusion in the treatment for back pain (Table 1). 
Bone chips were perfused with complete medium; this perfusate (diluted 1:1 with medium) 
was then carefully layered over Lymphoprep (Fresenius Kabi Norge, Norway). Mononuclear 
cells were isolated after being centrifuged at 900 g for 20 min, re-suspended in complete 
medium and centrifuged again at 750 g for 10 min. The resulting pellet was plated out in 
complete medium at a seeding density of 20 × 10
6
 cells per flask. After 24 h, non-adherent 
cells were removed by changing the medium and adherent cells were cultured in monolayer. 
Medium was changed every 2-3 days.  All cells were maintained in a humidified atmosphere 
at 5% CO2 and 21% O2 at 37°C. 
 
Calculation of doubling time 
To calculate doubling time (DT), cells were harvested, counted, and re-plated when they 
reached 70% confluency. Doubling time was calculated using the formula DT = (t2 − t1)ln 
(2)/ln (n2 / n1) where n2 is the cell number at harvesting, n1 is the cell number at plating, t2 
is the time at cell harvest and t1 is the time at plating [12].  
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Analysis of telomere length 
DNA was extracted from MC-MSC, WJ-MSC and BM-MSC every third passage using the 
High Pure PCR Template Preparation Kit (Roche, Sussex, UK) and stored at -20
o
C until 
needed. DNA content was measured using a NanoDrop (Fisher Scientific, Loughborough, 
UK).  The TeloTAGGG kit (Roche) was used to determine the length of telomeres from MC 
(n=2), WJ (n=2) and BM-MSC (n=1) over several passages according to the manufacturer’s 
instructions. 1 μg of genomic DNA from each sample population was digested with 
a HinfI/RsaI mixture for 2 h at 37°C and then loaded onto a 0.8 % agarose gel. The DNA 
fragments were separated by gel electrophoresis for 2–4 h at 70 V and transferred to a nylon 
membrane (Macherey-Nagel, Düren, Germany) by Southern blotting. 
The blotted DNA fragments were hybridized to a digoxigenin (DIG)-labelled probe specific 
for telomeric repeats and incubated with a DIG-specific antibody covalently coupled to 
alkaline phosphatase, which was visualised by the chemiluminescence substrate CDP-Star. 
The telomere bands were then demonstrated by exposing the blot to an X-ray film at room 
temperature for 15-20 min and the average terminal restriction fragment (TRF) length was 
determined by comparing the signals relative to the molecular weight standard. 
 
Immunocytochemistry 
The presence of pluripotency markers was assessed on MC-MSC (n=4), WJ-MSC (n=4) and 
BM-MSC (n=4) using antibodies against human OCT3/4 (Becton Dickinson & Company, 
Oxford, UK), nanog (R&D Systems, Oxford, UK) and REX-1 (Abcam, Cambridge, UK). 
Cells were seeded onto chamber slides at a density of 5000 per cm
2
, allowed to adhere 
overnight and then fixed with 4% paraformaldehyde for 20 min. Slides were washed twice 
with PBS before the addition of blocking buffer made up of 1% BSA, 0.1% Triton X-100 and 
10% normal serum of the appropriate species (i.e. donkey for nanog, goat serum for OCT3/4 
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and rabbit for REX-1) in PBS for 1 h at room temperature. Slides were washed twice in PBS 
before adding the primary antibodies against OCT3/4 (1:1000; (mouse IgG1 monoclonal), 
nanog (1:50; goat IgG polyclonal) and REX-1 (1:1000; rabbit IgG polyclonal) in the 
appropriate blocking buffer (containing the relevant serum above) and incubating overnight 
at 4
o
C. The primary antibodies were removed and the slides were washed twice with PBS.   
The relevant fluorophore-labelled secondary antibody (donkey-anti goat IgG Alexa Fluor 
488, goat-anti mouse IgG Alexa Fluor 488 or goat-anti rabbit Alexa Fluor 488) was diluted 
(1:250) in blocking buffer and added to the cells, which were then incubated in the dark for 1 
h at room temperature. Negative controls were obtained by using appropriate isotype 
antibodies or PBS in place of primary antibodies. Slides were washed twice with PBS before 
4’, 6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Peterborough, UK) stain was 
added to the cells as a counterstain to visualise cell nuclei, and the slides were then mounted 
and viewed under a Leica DMLB fluorescent microscope. The H9 ESC cell line was used as 
a positive control for the production of OCT3/4, nanog and REX-1, as previously described 
[13].   
 
Stimulation of cells with IFN-γ 
Human IFN-γ (Promokine, Heidelberg, Germany) was used to stimulate cells at a 
concentration of 25 ng/ml [14, 15].  It was added to the growth media of MC-MSC (n=4), 
WJ-MSC (n=4) and BM-MSC (n=4) cultured in monolayer at 37
o
C for 48 h, after which time 
cells were assessed for the production of co-stimulatory markers (CD40, 80 and 86), HLA-
DR and HLA-G, by flow cytometry and IDO by western blot and RT-qPCR. 
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Immunoprofiling 
Flow cytometry was used to assess the immunoprofile of UC-MSC (n=4) and BM-MSC 
(n=4). Cells at passage 3 were harvested, filtered through a 70 μM mesh cell strainer, 
pelleted, re-suspended in 2% bovine serum albumin (BSA) in PBS and counted. 100,000 
cells were used for each antibody and the control. Cells were stained with antibodies against 
SSEA-1, SSEA-4, alkaline phosphatase, TRA-1-60 and TRA-1-81 and then labelled with a 
secondary antibody conjugated to fluorescein isothiocyanate (FITC) (SouthernBiotech, 
Cambridge, UK). Co-stimulatory markers were all detected with phycoerythrin (PE)-
conjugated antibodies against CD40, CD80 and CD86 (Becton Dickinson & company, 
Oxford, UK). Antibodies to MHC II/HLA-DR were also PE conjugated (ImmunoTools, 
Friesoythe, Germany).  Appropriately isotype-matched antibodies were used as negative 
controls in all analyses and embryonic stem cells (ESC) were used as a positive control for 
these. The presence of HLA-G was also assessed using an anti HLA-G antibody (Santa-cruz, 
Texas, USA), both on the cell surface and internally, using a Cytofix/Cytoperm
TM
 plus 
Fixation/Permeabilisation Kit (Becton Dickinson & company, Oxford UK) according to the 
manufacturer’s instructions. Cells were analysed on a FACSCanto II flow cytometer using 
Diva 7 software (Becton Dickinson & company, Oxford UK). The human choriocarcinoma 
JEG3 cell line (ECACC, Salisbury, UK) was used as a positive control for  
HLA-G.  
 
Western blotting analysis of IDO 
Cells were lysed by the addition of cold lysis buffer (0.005% Tween 20, 0.5% Triton X-100 
at 4
o
C) containing a general protease inhibitor cocktail (Sigma-Aldrich, UK) at 1 ml per 10 x 
10
6
 cells.  Cell lysates were frozen and stored at -20
o
C until needed. Total protein 
concentrations were determined using the bicinchoninic acid (BCA) assay (Life 
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Technologies, UK) following the manufacturer’s protocol, to ensure equal protein loading 
onto the gel for each sample. 
Western blotting was used for the detection of IDO in whole cell lysates of MC-MSC, WJ-
MSC and BM-MSC. Electrophoresis was performed under reducing conditions by loading a 
20 μg protein sample into each well of a ready-made pre-cast NuPAGE 15-well Bis-Tris Mini 
4-12% gradient gel (Life Technologies). Proteins were then electroblotted onto nitrocellulose 
membranes using the iBlot system and iBlot gel nitrocellulose transfer stacks (Life 
Technologies). Antibody detection was carried out using iBlot western detection stacks and 
iBlot western detection chromogenic kits (Life Technologies). Briefly, the primary 
(monoclonal) antibodies against IDO (Abcam, Cambridge, UK; 1:500) were applied using 
the iBlot apparatus, followed by a secondary antibody (1:500) (Life Technologies) 
conjugated to horseradish peroxidase. Blots were then washed with Invitrogen wash solution 
three times, followed by a further two washes in autoclaved water. Finally the chromogenic 
substrate Novex
R
 Alkaline Phosphatase (Life Technologies) was applied to the membrane 
and colour development carried out for a maximum of 1 h at room temperature.  
 
Reverse transcriptase-quantitative PCR  
RNA was extracted from MC-MSC, WJ-MSC and BM-MSC before and after exposure to 
IFN-γ using the RNeasy Mini kit (Qiagen, Sussex, UK), following the manufacturer’s 
instructions.  RNA was eluted from the spin column with RNAse free water and stored at -
80°C until RT-qPCR analysis for IDO was performed using the SYBR green mastermix 
(Applied Biosystems, Warrington, UK) with GAPDH as a reference gene (Qiagen, 
QuantiTect Primer Assay). The reaction was conducted in the ABI 7500 RT-qPCR system 
(Applied Biosystems) at 95
o
C for 10 min followed by 40 cycles of 95
o
C for 15 seconds then 
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60
o
C for 1 min and data was captured using the SDS software (Applied Biosystems). The 
presence of the IDO mRNA in IFN-γ stimulated cells was expressed as a ratio compared to 
un-stimulated cells, using the comparative threshold method [16]. A 2-fold change threshold 
(up- or down-regulated) was deemed biologically significant. IDO gene expression was 
measured over a time course of exposure to IFN-γ between 1 and 48 hours, with the same 
time point representing the control in normal medium without the addition of the 
inflammatory cytokine. IDO mRNA levels were initially normalised to the reference gene 
before calculating the ratio of mRNA in the stimulated versus unstimulated cells. 
T cell isolation and co-culture with MSC 
Human naïve CD4
+
 T cells were isolated from heparinised blood using the naïve CD4
+
 
isolation kit II (Miltenyi Biotech, Cologne, Germany). For this, peripheral blood 
mononuclear cells (PBMCs) were isolated by density gradient centrifugation at 900 g for 20 
min over Lymphoprep. The buffy coat layer was re-suspended in cold PBS and washed 
several times to remove platelets. Cells were counted and re-suspended in buffer composed 
of 2mM EDTA (in 0.5%BSA) in PBS. Naïve CD4
+ 
T cell Biotin-Antibody Cocktail II was 
added and the cells were incubated for 10 min at 4
o
C.  The cells were then re-suspended in 1-
2 ml of EDTA buffer and centrifuged. Supernatant was aspirated and the cells were re-
suspended in EDTA/BSA buffer before adding anti-biotin microbeads, which were incubated 
for 15 min at 4
o
C. The cells were then washed and re-suspended in EDTA/BSA buffer prior 
to cell sorting via negative selection using a MACS column and separator magnet (Miltenyi 
Biotech, Cologne, Germany) as detailed in the manufacturer’s instructions. T cells were then 
labelled with Violet Proliferation Dye 450 (VPD450; BD HorizonTM, Oxford, UK) according 
to the manufacturer’s instructions. 
MC-MSC (n=3), WJ-MSC (n=3) and BM-MSC (n=3) were seeded into separate 24-well 
plates at a density of 10,000 cells per well. CD4
+
 T cells were added at a density of 100,000 
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cells per well to give a ratio of MSC:T cells of 1:10. Allogeneic stimulator human PBMCs 
from healthy donors were added at the same density with T cells and all cells were cultured at 
37
o
C in a humidified atmosphere for 5 days; after this time T cells were removed via gentle 
pipetting and analysed via flow cytometry using the violet laser for analysis of the VPD450 
dye and calculation of T cell proliferation.  The T cell response was analysed using the 
proliferation platform in FlowJo (Tree star, Oregon, USA). The percentage of dividing cells 
as well as the average number of cell divisions was calculated using the proliferation 
platform. Controls consisted of T cells alone and T cells with stimulator PBMCs, to check for 
lack of division and T cell division without suppression, respectively. All experiments were 
conducted in triplicate. 
Statistics  
GraphPad Prism was used for statistical analysis. Data is presented as mean ± standard error 
mean (SEM) and mean ± standard deviation (SD) in the graphs and text, respectively.  The 2-
way ANOVA and multiple t-test was used for growth kinetics analysis (Figure 1.A). Flow 
cytometry data showing the presence of pluripotency markers on MSC (Figure 2.B) and 
markers with and without IFN-γ stimulation (Figure 3) was analysed using 2-way ANOVA 
with Bonferroni’s multiple comparisons test.  Levels of significance are indicated as *p<0.05, 
**p<0.01 and ***p<0.001. 
 
Results and Discussion 
Longevity and telomere length  
The mean doubling time for MC-MSC (n=3) was 2-3 days up to passage 12-13, where 
growth slowed markedly, reducing to 20 days at passage 15-16 when experiments were 
stopped. In contrast, WJ-MSC (n=3) showed significantly slower growth (p=0.001 at P10-11, 
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p=0.01 at P11-12 and p=0.02 at P12-13), with mean doubling times of 4-5 days up to passage 
10-11 and 18 days at passage 11-12.  Both MC-MSC and WJ-MSC appeared larger and more 
spread at higher passages at the point cell growth started to slow (Figure 1.A), which may be 
indicative of senescence [17].  Previous work in our group showed BM-MSC had longer 
doubling times than these UC populations of MSC, of 5-6 days at passage 2 and 12 days at 
passage 3 [18].  Whilst longer doubling times of BM-MSC compared to UC-MSC has also 
been reported by other groups [14], our doubling times may be longer than that reported by 
other centres, since our group have not added  any specific growth factors . Many groups add 
growth factors such as fibroblastic growth factor-2 (FGF-2) to supplement BM-MSC culture 
medium, which is known to enhance their proliferation.  FGF-2 is secreted by MSC in culture 
but becomes depleted during serial passage in vitro if not supplemented [19, 20].  Another 
possible cause of observed differences between BM-MSC and other MSC tested in this work 
could be due to the fact that BM-MSC were obtained from older patients undergoing spinal 
fusion for back pain. In future work, BM from younger female donors may be a better source 
of MSC for comparison. 
Limited proliferative capacity could have implications in cell therapies that require high cell 
doses per kg of patient weight. For example, up to 10 million cells per kg of patient weight 
may be infused at several time-points for the treatment of graft-versus-host-disease (GVHD) 
with allogeneic MSC [21]. The differences in growth rate between MC-MSC and WJ-MSC 
shown in Figure 1.A may reflect heterogeneity of cells in cultures of MC-MSC, with a 
combination of different (sub) populations of cells possibly supporting better growth, in 
contrast to cells isolated from a single tissue source such as WJ.   The short (1 h) enzymatic 
digestion of sections of whole cord provided 6 x10
5
 (± 2.4 x10
4
) cells/g of cord (n=6) at 
passage 0-1. This is in accordance with Marmotti et al [22] who retrieved 6.6 x10
5
 cells/g 
UC, although that study used minced umbilical cord fragments in explant culture rather than 
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enzymatic digest. Furthermore, the average time taken from passage 0 to 1 was 8.8 days 
shorter for MC-MSC compared to WJ-MSC, with MC-MSC reaching passage 1 in an 
average time of 19.4 days ± 0.41 (n=9), whereas WJ-MSC took 28.2 ± 0.48 days (n=9) and 
yielded approximately 1.1 x10
6
 (± 2.5 x10
4
) cells/g WJ (n=5). BM-MSC were seeded at an 
average cell density of 20.2x10
6
 (± 4.5 x10
5
) (n=5) cells per 75cm
2
 and took 20.6 ± 2.14 days 
to reach passage 1.  Approximately 1.4 x10
6
 (± 2.0 x10
5
) BM-MSC were obtained from each 
sample of bone chip wash out treated with Lymphoprep.  
If cord cells are to be used to regenerate tissues then it is important that sufficient cells are 
grown from a single cord to allow full characterisation, but with a population growth that is 
also limited and non-tumorigenic and so likely to be safe. If all the MC-MSC were used from 
a single cord which weighs an average of 40g, taking into account the above yield of 0.6 
million cells/g of cord, we estimate that 8 x 10
14 
cells could be generated by passage 10. As 
an example of numbers of cells used in a clinical therapy, we currently use approximately 4 x 
10
6
 cells per patient to treat chondral defects with a mean size of 4 cm
2
. Thus 2 x 10
8
 doses 
could be used from one cord, which would therefore be 22 times more than required to treat 
the (estimated) 8.75 million people in the UK who have OA.   
Studies trying to determine whether in vitro expansion impacts on the genomic stability of 
MSC have shown that umbilical cord MSC senesce in culture at high passage [23], which we 
suggest is a desirable trait.  
We found that MC-MSC (n=3), WJ-MSC (n=3) and BM-MSC (n=1) all undergo telomere 
shortening during culture and with increasing passage number (Figure 1.B and C).  BM-MSC 
had a mean telomere length of 8 kpb at passage 3, which is in accordance with Marmotti et al 
[24] who reported that BM-MSC from 6 patients aged 20-30 years had telomere lengths in 
the range of 7.8–9.8 kbp. This is the same as that measured from matched samples of MC-
MSC and WJ-MSC from the same cord (patient 5, 33 year old mother) at passage 3. 
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However, the MC-MSC from the cord of baby from a 19 year old mother (patient 1) had 
longer telomeres at passage 3 (16.1 kpb) indicating individual variation in telomere length. It 
is unknown if maternal age could influence telomere length in foetal tissues. Paternal age has 
been shown to be significantly and positively associated with telomere length of both male 
and female offspring [25]. Nordfäll et al; [26] showed that telomere length is documented to 
have a hereditary component, with both paternal and x linked inheritance being proposed.  
However, large variations in telomere length between individuals of the same age have been 
shown in other studies [27] and could account for the differences seen between cells from 
different individuals in this study.  Similarly, Wang et al [21] reported that although UC-
MSC demonstrated shortening of their telomeres with increasing passage number, they also 
showed a degree of genomic instability over extended time in culture but did not undergo 
malignant transformation in small animal models. This is important from a safety point of 
view as the ability to maintain telomere length has been seen in cancer cells and germ cells 
and has been attributed to the cells’ ability to produce telomerase [28].  Vidal et al [29] 
reported that UC-MSCs have long telomere sequences and a greater expansion capability 
than BM-MSC, suggesting a late onset of senescence of this cell population during in vitro 
expansion.  
 
Pluripotency and expression of stage specific markers 
Results of immunocytochemistry for the embryonic stromal cell markers, OCT3/4, nanog and 
REX-1, which are critical for both self-renewal and maintenance of an undifferentiated state 
are shown for the MSC populations in Figure 2.A. None of the MSC, whether sourced from 
MC (n=4), WJ (n=4) or BM (n=4) showed positive staining for OCT3/4. However, 
differences were seen in the production of nanog and REX-1 between cell populations. BM-
MSC showed the least staining for nanog and REX-1 with MC-MSC showing the strongest 
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staining for both. As REX-1 is also a marker of proliferative capacity and MC-MSC showed 
shorter doubling times, it was expected that the intensity of REX-1 staining would be higher 
in these cells. OCT3/4, nanog and REX-1 are transcriptional activators, which can act 
together in concert to retain self-renewal and prevent differentiation. Reports differ on the 
presence of OCT3/4 on UC-MSC and BM-MSC, which is thought to be attributable to 
different culture conditions [30].  OCT3/4 can both activate and repress REX-1, which 
implies a dual regulatory ability. Nanog has also been shown to be a transcriptional activator 
of REX-1 and helps sustain its expression. MSC from both UC and adipose tissue have been 
found to express high levels of REX-1 and to proliferate rapidly in culture [31]. Our results 
support the findings that BM-MSC produce low levels of REX-1; others have also shown 
similar results and linked REX-1 production to the proliferative state of the cell [31]. The 
presence of other markers indicative of pluripotency, which are commonly expressed by ESC 
was assessed by flow cytometry. All MSC populations expressed low levels of SSEA-1, 
TRA-1-60 and TRA-1-81 (Figure 2.B). Approximately 12-15% of all populations were 
positive for SSEA-4 with no significant difference between MSCs from different localities 
(p=0.97), whereas significantly more BM-MSC were positive for alkaline phosphatase than 
MC-MSC or WJ-MSC (p = 0.02, Figure 2.B). SSEA-4 has been shown previously to be 
expressed by adult BM-MSC [14, 32, 33], although the reasons for adult MSC expressing 
embryonic markers remain unclear.  
The alkaline phosphatase antibody used in this study reacts with the tissue non-specific 
(TNS) isoform of alkaline phosphatase which is expressed at high levels in undifferentiated 
pluripotent stem cells [34] such as induced pluripotent stem cells and ESC.   Levels of TNS 
alkaline phosphatase decrease on differentiation (except if MSCs differentiate to bone), 
therefore this antibody is often used to monitor the differentiation status of pluripotent stem 
cells.   However, it is of note that as the isozyme of alkaline phosphatase is also the same as 
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that expressed by bone cells [35], it is also considered to be a general osteoblast marker [36, 
37].   Therefore the higher production seen in BM-MSC in this study may be explained by 
their higher propensity to differentiate to bone.  This is further supported by other studies 
showing that early osteogenic differentiation of BM-MSC relates to a significant increase in 
TNS alkaline phosphatase production [38]. Kim et al [38] also found that populations of BM-
MSC that were negative for alkaline phosphatase, expressed higher levels of REX-1 and 
nanog, as estimated using RT-qPCR, and were able to differentiate into multiple cell types 
better than their alkaline phosphatase positive counterparts. The implication is that alkaline 
phosphatase negative MSC retain a more primitive phenotype, which may indicate that UC-
MSC with their lower production of alkaline phosphatase are more primitive than BM-MSC. 
 
Production of immunomodulatory proteins before and after cell ‘licensing’ 
All cells were negative for the co-stimulatory markers, CD40, CD80, CD86 and HLA-DR in 
normal medium without IFN-γ (Figure 3.A.1). Significantly more BM-MSC (n=4) were 
positive for HLA-DR (41% ± 9%, p<0.001) after IFN-γ stimulation than MC-MSC (n=4) 
(3% ± 5%) or WJ-MSC (n=4), the proportion of which was the same +/- IFN-γ (8% ± 13%; 
Figure 3.A.2). None of the MSC populations produced IDO without IFN-γ stimulation, as 
shown by western blot and RT-qPCR analyses (Figure 3.B). However, following the addition 
of 25ng/ml IFN-γ, IDO was up-regulated by all cell populations within an hour of IFN-γ 
stimulation and continued to rise to the 48 h time point, although there were large differences 
between individuals.  
 
Co-stimulatory markers, such as CD40, 80 and 86, and HLA-DR are expressed on 
professional antigen presenting cells (APCs) of the immune system but are obviously 
undesirable on cells destined for cell therapies. CD40 is produced on dendritic cells, 
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macrophages and B cells, but it can also be found on other cell types such as endothelial 
cells, tumour cells and fibroblasts [39, 40]. In the presence of IFN-γ, BM-MSC up-regulate 
HLA-DR and have been found to be capable of functioning as APCs. In addition, they have 
also exhibited phagocytic properties reminiscent of professional immune cells [41]. Although 
an inflammatory stimulus, for example IFN-γ, up-regulates HLA-DR in BM-MSC, co-
stimulatory molecules are not produced [6, 14, 42].  If both HLA-DR and co-stimulatory 
molecules were to be present, an undesirable immune response could result [43], which may 
make these cells unsuitable for allogeneic use.   
 
IDO was up-regulated at the 48 h time point post IFN-γ stimulation for all MSC populations 
studied but to varying degrees within the cell source and individual. BMSC showed 1.4×10
3
, 
460×10
3
 and 159×10
3
 fold up-regulation, MC-MSC 65×10
3
, 61×10
3
 and 393×10
3
 fold, and 
WJ-MSC 9.5×10
3
, 22×10
3
 and 273×10
3
 fold (three patients per cell type). Other studies have 
also reported variable up-regulation of IDO between donors and suggest that the reason for 
this is the existence of an intrinsic variation in responsiveness and plasticity of MSC to 
inflammatory cytokines [6]. This suggests that it would be important for patients’ cells 
destined for allogeneic cell banks to have their immunomodulatory potential tested prior to 
banking, to assess the response to inflammatory cytokines for each donor. Table 1 shows the 
ages of all MSC donors used in this work, differences in IDO expression could not be 
correlated to patient age as donor ages for BM-MSC (up-regulating the highest to the lowest 
IDO) were 79, 31 and 48 years old, respectively. For MC-MSC, maternal ages were 39, 31 
and 22 years old, and for WJ-MSC, again from highest to lowest IDO expression, 22, 36 and 
39 years old. 
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HLA-G (Figure 3.C) was constitutively expressed by all cell types regardless of 
inflammatory stimulus, with the mean percentage of cells expressing positivity being 79% ± 
9% for MC-MSC, 66% ± 20% for WJ-MSC and 82% ± 12% for BM-MSC, without IFN-γ 
stimulation. There was no significant difference following IFN-γ stimulation, with 90% ± 
12% of MC-MSC, 58% ± 17% of  
 
WJ-MSC and 78% ± 11% of BM-MSC being positive in the presence of IFN-γ. HLA-G is an 
important immunomodulatory molecule, which has receptors on many subsets of immune 
cells and it is capable of inducing apoptosis of activated natural killer (NK) cells, CD4
+
 and 
CD8
+
 T cells. HLA-G is classically associated with protection of the foetus from maternal 
uterine NK cells. It is a ligand for NK cell inhibitory receptor (KIR2DL4) and therefore its 
production on the trophoblast cells of the placenta defend against NK cell-mediated death 
[44]. The production of HLA-G on MSC is likely to confer therapeutic benefit, by evading 
detection and destruction by the hosts’ immune system. Cells producing high levels of HLA-
G may also have the potential to calm inflammation [45], such as that which may be found in 
a degenerate or osteoarthritic joint [46]. Although IDO and HLA-G have been tested as 
immunosuppressive factors in this study, there are many others that are produced by MSC 
which may offer a potential therapeutic benefit.  For example, transforming growth factor- β 
(TGF-β), IL-10, Prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein 
(TSG6) have all been shown to have a role in reducing inflammation [47–49]. 
 
T cell proliferation assays 
Due to the large amount of literature available on the suppression of activated T cells and 
mixed lymphocytes by BM-MSC and UC-MSC, a simple co-culture method was used to 
determine if there were any differences between the populations of MSC examined in this 
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study (MC-MSC, WJ-MSC and BM-MSC) on T cell proliferation. Since cells currently used 
for regenerative medicine e.g. autologous chondrocyte implantation are applied after being 
cultured ‘unprimed’; we tested unprimed MSC without exposure to IFN-γ for the ability to 
supress T cell proliferation. Figure 4 shows that all MSC suppress proliferation of T cells 
with no significant difference between the cell populations. MC-MSC (n=3) suppressed T 
cell proliferation by 69% ± 5%, WJ-MSC (n=3) by 63% ± 1% and BM-MSC (n=3) by 75% ± 
4%. It is well known that MSC do not elicit a T cell response in vitro, and possess the 
capability to suppress activated T cells (CD4
+
 and CD8
+
), NK cells and B cells in vitro [14, 
50, 51]. The mechanisms of action are thought to be through paracrine effects (via 
immunomodulatory proteins such as HLA-G and IDO) and through cell-to-cell contact [47].  
 
Stimulated CD4
+
 T cells produce IFN-γ as part of the immune response (or in this case after 
stimulation with allogeneic PBMCs) [52–54].  Hence it is likely that the effects of co-culture 
of BM-MSC or UC-MSC on the suppression of T cells are due to the effects of HLA-G 
(which is produced by resting and primed MSC) [55] and immunomodulatory proteins 
produced by MSC after T cell produced IFN-γ.  Other studies show further enhancement of 
MSC mediated T cell suppression by priming MSC with IFN-γ prior to co-culture with 
activated T cells or mixed lymphocytes [14, 56].  
 
Conclusion 
The retrieval of sufficient numbers of MSC from aged patients for autologous cell therapy 
can be challenging and may be further complicated by donor site morbidity and painful 
harvesting procedures.  In addition, autologous therapy may be inappropriate for some 
patients if they have a particular genetic make-up, which is defective in terms of regeneration 
or maintenance of the appropriate extracellular matrix. UC-MSC may offer an alternative to 
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autologous therapies as they are easily sourced and expanded from waste tissue. However, 
reports in the literature vary on the characterisation of cells isolated from the distinct 
anatomical regions of the human UC and often favour the use of MSC isolated from WJ. In 
this study, we have applied an easy and rapid method to collect an adequate number of MC-
MSC (0.6 million cells/g cord tissue at passage 1), by simple mincing of the UC followed by 
a short (1 h) enzymatic digestion.  Conversely, to source WJ-MSC requires a more lengthy 
tissue dissection and 8.8 days longer in culture than MC-MSC to reach passage 1.  Although 
much work has been done on the immunomodulatory capacity of MSC from bone marrow 
and WJ, there are few reports on cells isolated from whole umbilical cord. Our results show 
that MC-MSC share many attributes with WJ-MSC and BM-MSC. However, they survive 
significantly longer in culture, proliferate faster and are easier to obtain, requiring minimal 
tissue manipulation and handling. This head-to-head comparison shows that MC-MSC offer a 
valuable and readily available source of cells with potential use in regenerative medicine. 
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Figure and table legends 
Figure 1.  Doubling time, cell morphology and telomere length of MC-MSC and WJ-
MSC over extended culture. A. Doubling time and representative cell morphology of MC-
MSC and WJ-MSC over an extended cell culture period in vitro. (n=3 for MC-MSC and WJ-
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MSC; scale bar represents 100 μm). Bars represent average doubling times at sequential 
passages ± SEM.  B.  Telomere length of MC-MSC, WJ-MSC (data shown from patient 1) 
and BM-MSC (patient 1) in culture at varying passage numbers. Black and white arrows 
indicate the positions of the terminal restriction fragments of the telomeres on the gel. C. 
Mean telomere length (kbp) for MC-MSC, WJ-MSC and BM-MSC at different passage 
numbers, showing shortening of telomeres with increasing time in culture. NT= not tested. 
Donor ages for cells used in the telomere experiment were as follows: BM-MSC Patient 1, 29 
years, MC-MSC and WJ-MSC Patient 1, 19 years, Patient 5, 33 years.  
 
Figure 2. Immunocytochemistry and flow cytometry showing the presence of 
pluripotency markers and stage specific embryonic antigens on BM-MSC, MC-MSC 
and WJ-MSC.  A. Immunocytochemical staining of BM-MSC, MC-MSC, WJ-MSC and H9 
ESC cell line with the pluripotency markers, OCT3/4, nanog and REX-1. Scale bars represent 
100 μm. B. The presence of stage specific embryonic antigens (SSEA)-1 and 4, tumour 
repressor antigens (TRA)-1-60, TRA-1-81 and the pluripotency marker alkaline phosphatase 
on MC-MSC, WJ-MSC and BM-MSC, assessed by flow cytometry. n=4 for each cell type. 
Bars represent average percentage of positively stained cells ± SEM. The ESC H9 cell line 
was also used as a positive control for the markers shown in B (data not shown). Levels of 
significance indicated are * p<0.05. 
 
Figure 3. Assessment of the production of co-stimulatory markers, HLA-DR and 
immunomodulatory proteins on BM-MSCs, MC-MSCs and WJ-MSCs before and after 
stimulation with IFN-γ.  A.1. Assessment of the production of the co-stimulatory markers 
(CD40, 80, 86) and MHC class II/HLA-DR on MC-MSC, WJ-MSC and BM-MSC (n=4 for 
each cell type) cultured in normal media without IFN-γ and (A.2) following stimulation with 
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25 ng/ml IFN-γ for 48h as assessed by flow cytometry.  B. Representative western blot 
showing the production of of IDO and the reference gene GAPDH in MC-MSC before and 
after stimulation with IFN-γ for 48h. The graph shows a 48h time course for the up-
regulation of IDO after stimulation with IFN-γ in MC-MSC, WJ-MSC and BM-MSC, 
analysed by RT qPCR.  C. Production of HLA-G, assessed by flow cytometry, on MC-MSC, 
WJ-MSC and BM-MSC cultured in normal media with no inflammatory stimulus and media 
with 25ng/ml IFN-γ  (n=4). Graphs present the average of values ± SEM. Levels of 
significance indicated are *** p<0.001. 
 
Figure 4. The suppression of T cell proliferation by resting MC-MSC, WJ-MSC and 
BM-MSC. Naïve  CD4
+
 T cells were labeled with violet proliferation dye and stimulated 
with allogeneic stimulator PBMCs (at a ratio of 1:1) in co-culture with either MC-MSC, WJ-
MSC and BM-MSC (T cell to MSC ratio of 10:1) for 5 days prior to flow cytometry analysis 
of the T cells to assess the proliferative response.  Each reaction was done in triplicate.  Data 
is expressed relative to T-cells and allogeneic stimulator PBMCs alone, without addition of 
MSC (assigned to 100% proliferation). The control shows T cell proliferation stimulated with 
allogeneic PBMCs alone without the addition of MSC. Data is shown as average percentage 
of T cell proliferation ± SEM.  n=3 for each cell type. 
 
 
Table 1. Patient data for BM-MSC, MC-MSC and WJ-MSC, showing the age of bone 
marrow donors and age of the mothers of umbilical cord donors.  The patients’ cells used 
in each experiment are indicated as follows: T = Telomere length, FC = flow cytometry 
(including pluripotency markers, co-stimulatory markers and HLA-DR), IDO= RT qPCR 
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data for IDO expression, HLA-G= flow cytometry for HLA-G, MLR= T cell and MSC co-
culture experiment. NT = not tested. 
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